Vanda's VQW — 765 misses primary endpoint in Phase III social anxiety trial
Vanda Pharmaceuticals put its VQW-765 program on hold pending further analysis following disappointing Phase III results. Results announced today showed the 546-adult social anxiety disorder trial missed its primary and key secondary endpoints. The findings did not confirm earlier Phase II results supporting the drug’s